Symbiotec Pharmalab - IPO Report

Symbiotec Pharmalab is an R&D-driven pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology and complex injectables. With over 30 years of experience, it has evolved from a steroidal-hormone API manufacturer into a backward-integrated platform serving both its own API portfolio and global customers through API products, CDMO services and complex injectables.

The company has a strong leadership position in corticosteroid and steroidal-hormone APIs, with FY26 global volume market shares of 38.2% and 23.8%, respectively, and is the only Indian and global company with presence across the top 10 APIs in these categories. Its portfolio comprises 44 active APIs across 10+ therapeutic areas, supported by 43 US DMFs and 23 valid CEPs, giving it a strong presence in regulated markets such as the US, Europe and Japan.

Its manufacturing platform includes 584.67 MT of chemical synthesis capacity and 700 KL of fermentation capacity, supported by three R&D centres focused on chemistry, biotechnology and complex injectables. These specialised capabilities and regulatory approvals create high entry barriers, while rising outsourcing and supply-chain diversification away from China provide opportunities to expand in the US and European markets.

Growth is being driven by portfolio diversification and expansion into higher-value opportunities, including classical and precision-fermentation APIs, immunosuppressants, anti-infectives, specialty ingredients and the generic version of Premarin. The company is also expanding its CDMO business through insulin, GLP-1 and classical fermentation contracts, while developing complex injectables under the US 505(b)(2) pathway.